RENAGADE Trademark

Trademark Overview


On Wednesday, February 24, 2021, a trademark application was filed for RENAGADE with the United States Patent and Trademark Office. The USPTO has given the RENAGADE trademark a serial number of 90545043. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Friday, August 30, 2024. This trademark is owned by Renagade Therapeutics LLC. The RENAGADE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances, namely, RNA and DNA therapeutics for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; pharmaceutical preparations, namely, RNA and DNA therapeutics for the prevention of osteoporosis; pharmaceutical preparations, namely, RNA and DNA therapeutics for the prevention of cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; pharmaceutical preparations, namely, RNA and DNA therapeutics for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations, namely, RNA and DNA therapeutics for the treatment of viral infections; pharmaceutical preparations, namely, RNA and DNA therapeutics for the treatment of cancers, neurological disorders, cardiovascula...
renagade

General Information


Serial Number90545043
Word MarkRENAGADE
Filing DateWednesday, February 24, 2021
Status732 - THIRD EXTENSION - GRANTED
Status DateFriday, August 30, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 17, 2023

Trademark Statements


Goods and ServicesPharmaceutical preparations and substances, namely, RNA and DNA therapeutics for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; pharmaceutical preparations, namely, RNA and DNA therapeutics for the prevention of osteoporosis; pharmaceutical preparations, namely, RNA and DNA therapeutics for the prevention of cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; pharmaceutical preparations, namely, RNA and DNA therapeutics for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations, namely, RNA and DNA therapeutics for the treatment of viral infections; pharmaceutical preparations, namely, RNA and DNA therapeutics for the treatment of cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; pharmaceutical preparations, namely, RNA and DNA therapeutics for treating diabetes; pharmaceutical preparations, namely, RNA and DNA therapeutics for use in chemotherapy; pharmaceutical preparations, namely, RNA and DNA therapeutics for cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; pharmaceutical preparations, namely, antivirals; therapeutic pharmaceuticals, namely, RNA and DNA therapeutics for the treatment of cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; vaccine preparations, namely, RNA and DNA vaccine preparations; vaccines, namely, RNA and DNA vaccines; anti-epileptic pharmaceutical preparations; Biometallic compounds being a component in pharmaceutical preparations for cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; human vaccine preparations, namely, RNA and DNA vaccine preparations; medical preparations for the treatment of cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; medicinal preparations for the treatment of infectious diseases and for use in oncology; mixed biological preparations, namely, RNA and DNA therapeutics for the prevention and treatment of infectious diseases; pharmaceutical preparations, namely, RNA and DNA therapeutics for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; pharmaceutical preparations for the treatment of viral diseases; pharmaceutical products, namely, RNA and DNA therapeutics for the treatment of joint disease; pharmaceutical products, namely, RNA and DNA therapeutics for the treatment of viral and infectious diseases, for the treatment of cancer; therapeutic vaccines, namely, RNA and DNA therapeutics; all of the foregoing excluding medicinal dietary and nutritional supplements
Pseudo MarkRENEGADE

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, May 26, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameRenagade Therapeutics LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressCambridge, MA 02142

Party NameRenagade Therapeutics LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressCambridge, MA 02142

Trademark Events


Event DateEvent Description
Saturday, February 27, 2021NEW APPLICATION ENTERED
Wednesday, May 26, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, September 15, 2021ASSIGNED TO EXAMINER
Wednesday, September 15, 2021NON-FINAL ACTION WRITTEN
Wednesday, September 15, 2021NON-FINAL ACTION E-MAILED
Wednesday, September 15, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, March 29, 2022TEAS PETITION TO REVIVE RECEIVED
Tuesday, March 29, 2022PETITION TO REVIVE-GRANTED
Tuesday, March 29, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, March 29, 2022ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Tuesday, March 29, 2022ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Wednesday, March 30, 2022NOTICE OF REVIVAL - E-MAILED
Thursday, March 31, 2022ASSIGNED TO LIE
Thursday, March 31, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, March 31, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, May 4, 2022FINAL REFUSAL WRITTEN
Wednesday, May 4, 2022FINAL REFUSAL E-MAILED
Wednesday, May 4, 2022NOTIFICATION OF FINAL REFUSAL EMAILED
Thursday, October 13, 2022TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, October 13, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, October 13, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, October 13, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, October 13, 2022APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, November 4, 2022TEAS REQUEST FOR RECONSIDERATION RECEIVED
Friday, November 4, 2022EXPARTE APPEAL RECEIVED AT TTAB
Friday, November 4, 2022JURISDICTION RESTORED TO EXAMINING ATTORNEY
Friday, November 4, 2022EX PARTE APPEAL-INSTITUTED
Monday, November 14, 2022ASSIGNED TO LIE
Monday, November 14, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, November 14, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, December 14, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 21, 2022EXPARTE APPEAL TERMINATED
Wednesday, December 28, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 17, 2023PUBLISHED FOR OPPOSITION
Tuesday, January 17, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 14, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, April 12, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, April 12, 2023SOU EXTENSION 1 FILED
Wednesday, April 12, 2023SOU EXTENSION 1 GRANTED
Friday, April 14, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, January 26, 2024SOU TEAS EXTENSION RECEIVED
Friday, January 26, 2024SOU EXTENSION 2 FILED
Friday, January 26, 2024SOU EXTENSION 2 GRANTED
Tuesday, January 30, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, August 30, 2024SOU TEAS EXTENSION RECEIVED
Friday, August 30, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, August 30, 2024SOU EXTENSION 3 FILED
Friday, August 30, 2024SOU EXTENSION 3 GRANTED